CIP2A polyclonal, anti-human

Background:
Cancerous inhibitor of protein phosphatase 2A (CIP2A), also designated p90 autoantigen or KIAA1524, is a single-pass membrane protein that exhibits oncogenic activity. CIP2A is known to inhibit PP2A (protein phosphatase 2A) dephosphorylation of c-Myc, thereby stabilizing c-Myc (an oncogenic transcription factor) and promoting tumor formation and malignant cell growth. PP2A is a trimeric protein complex consisting of three subunits: a scaffold subunit, a catalytic subunit and a regulatory subunit. CIP2A specifically interacts with the catalytic subunit of PP2A to inhibit its activity. Inhibition of PP2A activity is a crucial step allowing for the progression of human cell transformation. Further supporting its role as an oncoprotein, CIP2A is known to be overexpressed in colon, gastric, and head and neck squamous cell carcinomas.

Synonyms: CIP2A, KIAA1524, Protein CIP2A, p90

Cellular Location: Cytoplasm Cell membrane

Immunogen:
Recombinant protein of human CIP2A

Gene Symbol: CIP2A

Gene ID: 57650

Swiss prot: Q8TCG1

Calculated MW: 102kd

Recommended dilution:
WB 1:500-2000

Purity:
Affinity purification

Storage Buffer:
Buffer: PBS with 0.03% Proclin300, 50% glycerol, pH7.3.

Storage:
Store at -20℃. Avoid freeze / thaw cycles.